Clinical Trial

Disease: B-Cell Non-Hodgkin Lymphoma, NHL, (NCT05607420)

Disease info:

B-cell lymphoma refers to types of non-Hodgkin lymphoma that are characterised by abnormalities of the "B cells" (a type of white blood cell that makes antibodies to help fight infection). The condition may grow and spread slowly with few symptoms (also known as indolent lymphoma) or may be very aggressive with severe symptoms. 

Non-Hodgkin lymphoma (also known as non-Hodgkin’s lymphoma, NHL, or sometimes just lymphoma) is a cancer that starts in white blood cells called lymphocytes, which are part of the body’s immune system. NHL is a term that's used for many different types of lymphoma that all share some of the same characteristics. NHL usually starts in lymph nodes or other lymph tissue, but it can sometimes affect the skin. Non-Hodgkin lymphoma is one of the most common cancers in the United States, accounting for about 4% of all cancers.

Relapsed refers to when a patient has received active treatment, went off treatment and then the disease came back, whereas refractory refers to disease that is progressing despite active treatment.


B-cell NHL is the most common type of non-Hodgkin lymphoma. NHL accounts for about 4% of all cancers in the U.S. The American Cancer Society estimates 80,550 people will be diagnosed with NHL in 2023.
Official title:
Open-label Dose-finding and Dose-expansion Study to Evaluate the Safety, Expansion, Persistence, and Clinical Activity of UCART20x22 in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (B-NHL)


Cellectis Central Contact

Phone: +1 (347) 752-4044



United States, Illinois
University of Chicago, Chicago, Illinois, United States, 60637

United States, Massachusetts 
Massachusetts General Hospital, Boston, Massachusetts, United States, 02114

United States, New Jersey 
Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States, 08901

United States, Texas 
Sarah Cannon - St. David South Austin Medical Center, Austin, Texas, United States, 78704

France, Auvergne Rhone Alpe
Hôpital Lyon Sud, Pierre-Bénite, Auvergne Rhone Alpe, France, 69310

France, Ile De France 
Hôpital Saint Louis, Paris, Ile De France, France, 75010

France, Occitanie 
CHU de Montpellier, Montpellier, Occitanie, France, 34295

Spain, Navarra 
Clínica Universidad de Navarra, Pamplona, Navarra, Spain, 31008

Spain, Sevilla
Hospital Universitario Virgen del Rocío, Sevilla, Spain, 41013

Study start:
Nov. 1, 2022
80 participants
Gene editing method:
Type of edit:
Gene knock-out
T Cell Receptor Alpha Constant (TRAC) and CD52
Delivery method:
Lentivirus - Ex-vivo
IND Enabling Pre-clinical
Phase I Safety
Phase II Safety and Dosing
Phase III Safety and Efficacy

Status: Active recruiting


First-in-human, open-label, dose-finding and dose-expansion study of UCART20x22 administered intravenously in subjects with relapsed or refractory B-Cell Non-Hodgkin Lymphoma (B-NHL). The purpose of this study is to evaluate the safety and clinical activity of UCART20x22 and determine the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D).

Last updated: Mar. 3, 2024
Search CRISPR Medicine